Drug Trial Radar · NCT07872423
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jan 27, 2025
Primary completion
Jun 9, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Beijing VDJBio Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to treat idiopathic multicenter Castleman disease (iMCD).
Conditions
- Anti IL-6R
- Castleman's Disease, Multicentric
Interventions
Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody InjectionDrug
VDJ001 is a recombinant humanized monoclonal antibody targeting the interleukin-6 receptor (IL-6R). It is produced using Chinese hamster ovary (CHO) cells through DNA recombinant technology. The antibody specifically binds to both soluble and membrane-bound IL-6R (sIL-6R and mIL-6R), thereby inhibiting signal transduction mediated by sIL-6R or mIL-6R.
PlaceboDrug
This is a matching placebo formulation containing no active pharmaceutical ingredient (API). The placebo is manufactured to be identical in appearance, color, shape, size, taste, and packaging to the investigational product VDJ001 to maintain the integrity of the double-blind design. It is utilized solely as a control intervention for the purpose of this randomized, double-blind, placebo-controlled clinical trial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients achieving a comprehensive response, defined as complete response (CR) or partial response (PR), sustained for at least 18 weeks, based on combined assessment of symptoms, biochemical efficacy, and overall lymph node evaluation.Time frame: 30/36 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Xiamen Branch,Zhongshan hospital,Fudan University
Xiamen, Fujian, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Suncy0618@163.Com
Chengdu, Sichuan, China · Not yet recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.